LONDON, March 27 /PRNewswire-FirstCall/ -- SkyePharma PLC announces today that the Company will issue its financial results for the year ended 31 December 2005 to the London Stock Exchange at 07:00 a.m. (BST) on Wednesday 19 April 2006. Later that morning the Company will host an analyst presentation, which will be webcast live, to be followed by a US conference call.
Frank Condella, SkyePharma’s Chief Executive Officer, will host the analyst presentation and the conference call. Investors and other interested parties may view the live webcast at 10:00 a.m. (BST) on the Company’s website at www.skyepharma.com under the Investor Relations tab.
US investors and other interested parties may access the conference call at 10:00 a.m. EDT (15:00 BST) by dialling 1-800-762-6067 for US participants and +1-480-629-9566 for international participants. The slides of the presentation will be available on the Company’s website at www.skyepharma.com under the Investor Relations tab.
For those unable to listen to the live broadcast, a replay will be available shortly after the conference call by dialling 1-800-475-6701 for US participants and +1-320-365-3844 for international participants and entering Access Code 824129.
A Business Review meeting will be held on Wednesday 21 June 2006 at the offices of Buchanan Communications, 45 Moorfields, London and will start at 09:30 a.m. Attendance is by invitation only but the meeting will be webcast. Further details of the agenda for this meeting will be published nearer the day. This meeting will provide an opportunity to gain an in-depth awareness and understanding of key products in our portfolio and pipeline and to meet members of our senior management team.
For further information please contact: SkyePharma PLC +44 207 491 1777 Frank Condella, Chief Executive Officer Peter Laing, Director of Corporate Communications +44 207 491 5124 Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000 Tim Anderson / Mark Court / Rebecca Skye Dietrich About SkyePharma
SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now eleven approved and marketed products incorporating SkyePharma’s technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit www.skyepharma.com.
Certain statements in this news release are forward-looking statements and are made in reliance on the safe harbour provisions of the U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will materialize. Because the expectations are subject to risks and uncertainties, actual results may vary significantly from those expressed or implied by the forward-looking statements based upon a number of factors, which are described in SkyePharma’s 20-F and other documents on file with the SEC. Factors that could cause differences between actual results and those implied by the forward-looking statements contained in this news release include, without limitation, risks related to the development of new products, risks related to obtaining and maintaining regulatory approval for existing, new or expanded indications of existing and new products, risks related to SkyePharma’s ability to manufacture products on a large scale or at all, risks related to SkyePharma’s and its marketing partners’ ability to market products on a large scale to maintain or expand market share in the face of changes in customer requirements, competition and technological change, risks related to regulatory compliance, the risk of product liability claims, risks related to the ownership and use of intellectual property, and risks related to SkyePharma’s ability to manage growth. SkyePharma undertakes no obligation to revise or update any such forward-looking statement to reflect events or circumstances after the date of this release.
SkyePharma PLC
CONTACT: SkyePharma PLC, +44-207-491-1777, or Frank Condella, ChiefExecutive Officer, SkyePharma PLC, or Peter Laing, Director of CorporateCommunications of SkyePharma PLC, +44-207-491-5124, or Sandra Haughton, USInvestor Relations of SkyePharma PLC, +1-212-753-5780; or BuchananCommunications, Tim Anderson, or Mark Court, or Rebecca Skye Dietrich,+44-207-466-5000
Web site: http://www.skyepharma.com/
